Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML

被引：48

作者：

Maziarz, Richard Thomas T. ^{[1
]}

Patnaik, Mrinal M. ^{[2
]}

Scott, Bart L. ^{[3
]}

Mohan, Sanjay R. ^{[4
]}

Deol, Abhinav ^{[5
]}

Rowley, Scott D. ^{[6
,7
]}

Kim, Dennis ^{[8
]}

Haines, Kelly ^{[9
]}

Bonifacio, Gaetano J. ^{[9
]}

Rine, Patrice ^{[9
]}

Purkayastha, Das ^{[9
]}

Fernandez, Hugo F. ^{[10
]}

机构：

[1] OR Hlth Sci Univ, Ctr Hematol Malignancies, Portland, OR USA

[2] Mayo Clin, Div Hematol, Rochester, MN USA

[3] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[4] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Myeloma Div, Hackensack, NJ USA

[7] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[8] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Novartis Pharmaceut, E Hanover, NJ USA

[10] Mem Healthcare Syst, Moffitt Canc Ctr, Dept Malignant Hematol & Cellular Therapy, Pembroke Pines, FL USA

来源：

关键词：

D O I：

10.1182/blood-2018-99-113582

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

662

引用

页数：3